1. P157. Identifying factors within the sentinel lymph node biopsy to guide decisions regarding additional axillary treatment in women with early breast cancer
- Author
-
Laszlo Romics, Julie Doughty, Mark Corrigan, E. O'Connell, Sheila Stallard, J. Mansell, and Claire Rutherford
- Subjects
medicine.medical_specialty ,medicine.diagnostic_test ,business.industry ,General surgery ,Sentinel lymph node ,BRCA mutation ,General Medicine ,medicine.disease ,Breast cancer ,Oncology ,Seroma ,Biopsy ,Medicine ,Surgery ,Smoking status ,Implant ,business ,Early breast cancer - Abstract
patient records, nursing and medical notes. Data analysed using SPSS version 22. Results: Twenty-one patients with 26 TiLOOP assisted reconstructions with a mean follow up of 194 days (range 9e430) were analysed. Patients were a median age 51 (range 32e79) and median BMI of 25 (range 21e34). The majority had physical hobbies (n 1⁄4 16), no major comorbidities (n 1⁄4 17) and one was a smoker. The majority (n 1⁄4 19) stated the desire for a simple reconstructive option and were satisfied with their current breast size (n 1⁄4 18). 19 had in-situ or invasive breast cancer (n 1⁄4 13 screen-detected), 2 were risk reducing (proven BRCA mutation). Complications included: 1 haematoma; 5 seromas requiring single (40e150ml) aspiration; 3 with seroma treated as suspected minor infection with oral antibiotics. One implant loss was seen in this series. There was no correlation of complications with cup size, comorbidities or smoking status. Conclusions: TiLOOP is an economical non-autologous material available to provide lower-pole support and facilitate one-stage implantbased IBR, which is associated with a low complication rate.
- Published
- 2015
- Full Text
- View/download PDF